{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:37:15Z","timestamp":1792532235834,"version":"4.5.0"},"reference-count":291,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The discovery of the link between microRNAs (miRNAs) and a myriad of human diseases, particularly various cancer types, has generated significant interest in exploring their potential as a novel class of drugs. This has led to substantial investments in interdisciplinary research fields such as biology, chemistry, and medical science for the development of miRNA-based therapies. Furthermore, the recent global success of SARS-CoV-2 mRNA vaccines against the COVID-19 pandemic has further revitalized interest in RNA-based immunotherapies, including miRNA-based approaches to cancer treatment. Consequently, RNA therapeutics have emerged as highly adaptable and modular options for cancer therapy. Moreover, advancements in RNA chemistry and delivery methods have been pivotal in shaping the landscape of RNA-based immunotherapy, including miRNA-based approaches. Consequently, the biotechnology and pharmaceutical industry has witnessed a resurgence of interest in incorporating RNA-based immunotherapies and miRNA therapeutics into their development programs. Despite substantial progress in preclinical research, the field of miRNA-based therapeutics remains in its early stages, with only a few progressing to clinical development, none reaching phase III clinical trials or being approved by the US Food and Drug Administration (FDA), and several facing termination due to toxicity issues. These setbacks highlight existing challenges that must be addressed for the broad clinical application of miRNA-based therapeutics. Key challenges include establishing miRNA sensitivity, specificity, and selectivity towards their intended targets, mitigating immunogenic reactions and off-target effects, developing enhanced methods for targeted delivery, and determining optimal dosing for therapeutic efficacy while minimizing side effects. Additionally, the limited understanding of the precise functions of miRNAs limits their clinical utilization. Moreover, for miRNAs to be viable for cancer treatment, they must be technically and economically feasible for the widespread adoption of RNA therapies. As a result, a thorough risk evaluation of miRNA therapeutics is crucial to minimize off-target effects, prevent overdosing, and address various other issues. Nevertheless, the therapeutic potential of miRNAs for various diseases is evident, and future investigations are essential to determine their applicability in clinical settings.<\/jats:p>","DOI":"10.3390\/ijms25031469","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T03:59:42Z","timestamp":1706155182000},"page":"1469","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":389,"title":["Trials and Tribulations of MicroRNA Therapeutics"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1276-8466","authenticated-orcid":false,"given":"Attila A.","family":"Seyhan","sequence":"first","affiliation":[{"name":"Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA"},{"name":"Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA"},{"name":"Joint Program in Cancer Biology, Lifespan Health System and Brown University, Providence, RI 02912, USA"},{"name":"Legorreta Cancer Center, Brown University, Providence, RI 02912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rands, C.M., Meader, S., Ponting, C.P., and Lunter, G. (2014). 8.2% of the Human genome is constrained: Variation in rates of turnover across functional element classes in the human lineage. PLoS Genet., 10.","DOI":"10.1371\/journal.pgen.1004525"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature11247","article-title":"An integrated encyclopedia of DNA elements in the human genome","volume":"489","author":"Dunham","year":"2012","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-022-04965-x","article-title":"The sequences of 150,119 genomes in the UK Biobank","volume":"607","author":"Halldorsson","year":"2022","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cell.2009.12.023","article-title":"Transcriptional control of gene expression by microRNAs","volume":"140","author":"Khraiwesh","year":"2010","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3389\/fpls.2017.00565","article-title":"MicroRNA and Transcription Factor: Key Players in Plant Regulatory Network","volume":"8","author":"Samad","year":"2017","journal-title":"Front. Plant Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"D253","DOI":"10.1093\/nar\/gky1023","article-title":"TransmiR v2.0: An updated transcription factor-microRNA regulation database","volume":"47","author":"Tong","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1039\/C5MB00064E","article-title":"microRNAs with different functions and roles in disease development and as potential biomarkers of diabetes: Progress and challenges","volume":"11","author":"Seyhan","year":"2015","journal-title":"Mol. Biosyst."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1515\/BC.2005.139","article-title":"microRNA-guided posttranscriptional gene regulation","volume":"386","author":"Chen","year":"2005","journal-title":"Biol. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Catalanotto, C., Cogoni, C., and Zardo, G. (2016). MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17101712"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation","volume":"9","author":"Hayder","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"108123","DOI":"10.1016\/j.pharmthera.2022.108123","article-title":"Review: RNA-based diagnostic markers discovery and therapeutic targets development in cancer","volume":"234","author":"Wang","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1038\/srep05150","article-title":"Genome-wide survey of tissue-specific microRNA and transcription factor regulatory networks in 12 tissues","volume":"4","author":"Guo","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1126\/science.1114519","article-title":"MicroRNA expression in zebrafish embryonic development","volume":"309","author":"Wienholds","year":"2005","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"18017","DOI":"10.1073\/pnas.0508823102","article-title":"Drosophila microRNAs exhibit diverse spatial expression patterns during embryonic development","volume":"102","author":"Aboobaker","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.gep.2008.03.002","article-title":"Expression of microRNAs during embryonic development of Xenopus tropicalis","volume":"8","author":"Walker","year":"2008","journal-title":"Gene Expr. Patterns"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.gpb.2012.07.005","article-title":"MicroRNAs in Common Human Diseases","volume":"10","author":"Li","year":"2012","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.clinbiochem.2013.03.015","article-title":"Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: Promises and challenges","volume":"46","author":"Robitaille","year":"2013","journal-title":"Clin. Biochem."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Condrat, C.E., Thompson, D.C., Barbu, M.G., Bugnar, O.L., Boboc, A., Cretoiu, D., Suciu, N., Cretoiu, S.M., and Voinea, S.C. (2020). miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells, 9.","DOI":"10.3390\/cells9020276"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ncrna.2023.07.002","article-title":"MiRNAs and lncRNAs in the regulation of innate immune signaling","volume":"8","author":"Gareev","year":"2023","journal-title":"Noncoding RNA Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaut.2009.02.012","article-title":"MicroRNA in autoimmunity and autoimmune diseases","volume":"32","author":"Pauley","year":"2009","journal-title":"J. Autoimmun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molcel.2005.09.012","article-title":"MicroRNAs and viral infection","volume":"20","author":"Sullivan","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.micro.112408.134243","article-title":"Viruses, microRNAs, and host interactions","volume":"64","author":"Skalsky","year":"2010","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Barbu, M.G., Condrat, C.E., Thompson, D.C., Bugnar, O.L., Cretoiu, D., Toader, O.D., Suciu, N., and Voinea, S.C. (2020). MicroRNA Involvement in Signaling Pathways During Viral Infection. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00143"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jare.2020.11.013","article-title":"Micro-RNAs in the regulation of immune response against SARS CoV-2 and other viral infections","volume":"30","author":"AlHajri","year":"2021","journal-title":"J. Adv. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3389\/fphys.2012.00476","article-title":"Circulating microRNAs: Promising candidates serving as novel biomarkers of acute hepatitis","volume":"3","author":"Elfimova","year":"2012","journal-title":"Front. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Li, Y.J., Xu, M., Gao, Z.H., Wang, Y.Q., Yue, Z., Zhang, Y.X., Li, X.X., Zhang, C., Xie, S.Y., and Wang, P.Y. (2013). Alterations of serum levels of BDNF-related miRNAs in patients with depression. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063648"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/13543784.2014.997873","article-title":"Thinking small: Towards microRNA-based therapeutics for anxiety disorders","volume":"24","author":"Scott","year":"2015","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.neurobiolaging.2010.04.034","article-title":"MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer\u2019s-associated pathogenesis in SAMP8 mice","volume":"33","author":"Liu","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(11)70070-9","article-title":"Development of biomarkers for Huntington\u2019s disease","volume":"10","author":"Weir","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2169\/internalmedicine.50.5129","article-title":"Circulating microRNAs are promising novel biomarkers of acute myocardial infarction","volume":"50","author":"Wang","year":"2011","journal-title":"Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/1354750X.2013.833294","article-title":"Conventional and novel diagnostic biomarkers of acute myocardial infarction: A promising role for circulating microRNAs","volume":"18","author":"Recchioni","year":"2013","journal-title":"Biomarkers"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ijo.2017.84","article-title":"Gastric bypass surgery with exercise alters plasma microRNAs that predict improvements in cardiometabolic risk","volume":"41","author":"Coen","year":"2017","journal-title":"Int. J. Obes."},{"key":"ref_34","first-page":"7351902","article-title":"Elevated and Correlated Expressions of miR-24, miR-30d, miR-146a, and SFRP-4 in Human Abdominal Adipose Tissue Play a Role in Adiposity and Insulin Resistance","volume":"2018","author":"Garufi","year":"2018","journal-title":"Int. J. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1096\/fj.08-112326","article-title":"MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy","volume":"22","author":"Wang","year":"2008","journal-title":"FASEB J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"31479","DOI":"10.1038\/srep31479","article-title":"Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: A pilot cross-sectional study","volume":"6","author":"Seyhan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_37","first-page":"106","article-title":"Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes","volume":"13","author":"Garufi","year":"2016","journal-title":"Mol. Biosyst."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jnutbio.2017.08.007","article-title":"Circulating levels of miR-7, miR-152 and miR-192 respond to vitamin D supplementation in adults with prediabetes and correlate with improvements in glycemic control","volume":"49","author":"Pittas","year":"2017","journal-title":"J. Nutr. Biochem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/path.1825","article-title":"BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas","volume":"207","author":"Kluiver","year":"2005","journal-title":"J. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs\u2014microRNAs with a role in cancer","volume":"6","author":"Slack","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11060-009-9843-2","article-title":"Emerging functions of microRNAs in glioblastoma","volume":"92","author":"Lawler","year":"2009","journal-title":"J. Neurooncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cell.2009.02.005","article-title":"MicroRNAs and cancer: Short RNAs go a long way","volume":"136","author":"Ventura","year":"2009","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fgene.2013.00258","article-title":"Epigenetic alteration and microRNA dysregulation in cancer","volume":"4","author":"Suzuki","year":"2013","journal-title":"Front. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-pathol-012513-104715","article-title":"MicroRNAs in cancer","volume":"9","author":"Garofalo","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","article-title":"MicroRNAs in cancer: Biomarkers, functions and therapy","volume":"20","author":"Hayes","year":"2014","journal-title":"Trends Mol. Med."},{"key":"ref_47","first-page":"59","article-title":"Critical analysis of the potential for microRNA biomarkers in breast cancer management","volume":"7","author":"Graveel","year":"2015","journal-title":"Breast Cancer Dove Med. Press"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"re3","DOI":"10.1126\/scisignal.2005825","article-title":"Dysregulation of microRNA biogenesis and gene silencing in cancer","volume":"8","author":"Hata","year":"2015","journal-title":"Sci. Signal"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc3932","article-title":"MicroRNA biogenesis pathways in cancer","volume":"15","author":"Lin","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10409238.2015.1117054","article-title":"Dysregulation of microRNA biogenesis machinery in cancer","volume":"51","author":"Hata","year":"2016","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1158\/0008-5472.CAN-17-1767","article-title":"miR-6883 Family miRNAs Target CDK4\/6 to Induce G(1) Phase Cell-Cycle Arrest in Colon Cancer Cells","volume":"77","author":"Lulla","year":"2017","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.2174\/1568026619666181120121830","article-title":"MicroRNAs as Therapeutic Agents: The Future of the Battle Against Cancer","volume":"18","author":"Biswas","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2147\/OTT.S152462","article-title":"Functional miRNAs in breast cancer drug resistance","volume":"11","author":"Hu","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3389\/fgene.2019.00933","article-title":"Comprehensive Analysis of Human microRNA-mRNA Interactome","volume":"10","author":"Plotnikova","year":"2019","journal-title":"Front. Genet."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Ali Syeda, Z., Langden, S.S.S., Munkhzul, C., Lee, M., and Song, S.J. (2020). Regulatory Mechanism of MicroRNA Expression in Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051723"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"581007","DOI":"10.3389\/fonc.2020.581007","article-title":"microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis","volume":"10","author":"Annese","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.7150\/jca.39044","article-title":"MicroRNA-183 in Cancer Progression","volume":"11","author":"Cao","year":"2020","journal-title":"J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Fathi, M., Ghafouri-Fard, S., Abak, A., and Taheri, M. (2021). Emerging roles of miRNAs in the development of pancreatic cancer. Biomed. Pharmacother., 141.","DOI":"10.1016\/j.biopha.2021.111914"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/nar\/gkaa1223","article-title":"A pan-cancer atlas of somatic mutations in miRNA biogenesis genes","volume":"49","author":"Nawrocka","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s10038-021-00938-6","article-title":"Cancer-associated miRNAs and their therapeutic potential","volume":"66","author":"Inoue","year":"2021","journal-title":"J. Hum. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Pajares, M.J., Alemany-Cosme, E., Goni, S., Bandres, E., Palanca-Ballester, C., and Sandoval, J. (2021). Epigenetic Regulation of microRNAs in Cancer: Shortening the Distance from Bench to Bedside. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147350"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Smolarz, B., Durczy\u0144ski, A., Romanowicz, H., and Hogendorf, P. (2021). The Role of microRNA in Pancreatic Cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101322"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Smolarz, B., Durczy\u0144ski, A., Romanowicz, H., Szy\u0142\u0142o, K., and Hogendorf, P. (2022). miRNAs in Cancer (Review of Literature). Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052805"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Menon, A., Abd-Aziz, N., Khalid, K., Poh, C.L., and Naidu, R. (2022). miRNA: A Promising Therapeutic Target in Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911502"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Raufi, A.G., May, M.S., Hadfield, M.J., Seyhan, A.A., and El-Deiry, W.S. (2023). Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24044238"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1083382","DOI":"10.3389\/fendo.2023.1083382","article-title":"DICER1 RNase IIIb domain mutations trigger widespread miRNA dysregulation and MAPK activation in pediatric thyroid cancer","volume":"14","author":"Reichenberger","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Seyhan, A.A. (2023). Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer-Advances and Challenges. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713340"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1038\/s41388-023-02801-8","article-title":"A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy","volume":"42","author":"Abdelaal","year":"2023","journal-title":"Oncogene"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/cr.2011.158","article-title":"Exogenous plant MIR168a specifically targets mammalian LDLRAP1: Evidence of cross-kingdom regulation by microRNA","volume":"22","author":"Zhang","year":"2012","journal-title":"Cell Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4161\/rna.21619","article-title":"XenomiRs and miRNA homeostasis in health and disease: Evidence that diet and dietary miRNAs directly and indirectly influence circulating miRNA profiles","volume":"9","author":"Witwer","year":"2012","journal-title":"RNA Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1039\/C4FO01119H","article-title":"Food derived microRNAs","volume":"6","author":"Wagner","year":"2015","journal-title":"Food Funct."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/advances\/nmy127","article-title":"Dietary microRNA-A Novel Functional Component of Food","volume":"10","author":"Zhang","year":"2019","journal-title":"Adv. Nutr."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"586564","DOI":"10.3389\/fnut.2021.586564","article-title":"Potential Mechanisms Linking Food-Derived MicroRNAs, Gut Microbiota and Intestinal Barrier Functions in the Context of Nutrition and Human Health","volume":"8","author":"Aranaz","year":"2021","journal-title":"Front. Nutr."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3934\/Allergy.2023008","article-title":"Dietary and orally-delivered miRNAs: Are they functional and ready to modulate immunity?","volume":"7","author":"Bryniarski","year":"2023","journal-title":"AIMS Allergy Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nbt.2737","article-title":"Lack of detectable oral bioavailability of plant microRNAs after feeding in mice","volume":"31","author":"Dickinson","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging concepts of miRNA therapeutics: From cells to clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends Genet."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Arif, K.M.T., Elliott, E.K., Haupt, L.M., and Griffiths, L.R. (2020). Regulatory Mechanisms of Epigenetic miRNA Relationships in Human Cancer and Potential as Therapeutic Targets. Cancers, 12.","DOI":"10.3390\/cancers12102922"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6443","DOI":"10.1016\/j.csbj.2022.11.036","article-title":"Consequences of genetic variants in miRNA genes","volume":"20","author":"Machowska","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/0008-5472.CAN-23-0296","article-title":"KRAS Hijacks the miRNA Regulatory Pathway in Cancer","volume":"83","author":"Bortoletto","year":"2023","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2017.10.010","article-title":"Translation of noncoding RNAs: Focus on lncRNAs, pri-miRNAs, and circRNAs","volume":"361","author":"Li","year":"2017","journal-title":"Exp. Cell Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Invest. New Drugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Desantis, V., Saltarella, I., Lamanuzzi, A., Melaccio, A., Solimando, A.G., Mariggi\u00f2, M.A., Racanelli, V., Paradiso, A., Vacca, A., and Frassanito, M.A. (2020). MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093084"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0092-8674(93)90530-4","article-title":"Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans","volume":"75","author":"Wightman","year":"1993","journal-title":"Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/35040556","article-title":"Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA","volume":"408","author":"Pasquinelli","year":"2000","journal-title":"Nature"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygeno.2010.03.009","article-title":"Identification of homologous microRNAs in 56 animal genomes","volume":"96","author":"Li","year":"2010","journal-title":"Genomics"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Friedl\u00e4nder, M.R., Lizano, E., Houben, A.J.S., Bezdan, D., B\u00e1\u00f1ez-Coronel, M., Kudla, G., Mateu-Huertas, E., Kagerbauer, B., Gonz\u00e1lez, J., and Chen, K.C. (2014). Evidence for the biogenesis of more than 1000 novel human microRNAs. Genome Biol., 15.","DOI":"10.1186\/gb-2014-15-4-r57"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"D140","DOI":"10.1093\/nar\/gkj112","article-title":"miRBase: microRNA sequences, targets and gene nomenclature","volume":"34","author":"Grocock","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00018-018-2940-7","article-title":"Regulatory network of miRNA on its target: Coordination between transcriptional and post-transcriptional regulation of gene expression","volume":"76","author":"Pu","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/CIRCRESAHA.110.227496","article-title":"The art of microRNA research","volume":"108","year":"2011","journal-title":"Circ. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1101\/gr.082701.108","article-title":"Most mammalian mRNAs are conserved targets of microRNAs","volume":"19","author":"Friedman","year":"2009","journal-title":"Genome Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/nbt.3947","article-title":"An integrated expression atlas of miRNAs and their promoters in human and mouse","volume":"35","author":"Abugessaisa","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1479-5876-8-48","article-title":"Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients","volume":"8","author":"Gambardella","year":"2010","journal-title":"J. Transl. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1158\/0008-5472.CAN-12-0803","article-title":"Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia","volume":"72","author":"Baer","year":"2012","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11060-017-2414-z","article-title":"Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: A CBTRUS Report","volume":"133","author":"Achey","year":"2017","journal-title":"J. Neurooncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1056\/NEJMcibr051201","article-title":"MicroRNA and lung cancer","volume":"352","author":"Eder","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Allen, J.E., Crowder, R.N., and El-Deiry, W.S. (2015). First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143082"},{"key":"ref_101","first-page":"207","article-title":"Prognostic Value of miRNA-155 Expression in B-Cell Non-Hodgkin Lymphoma","volume":"34","author":"Bedewy","year":"2017","journal-title":"Turk. J. Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.neo.2017.10.002","article-title":"Role of Dopamine Receptors in the Anticancer Activity of ONC201","volume":"20","author":"Kline","year":"2018","journal-title":"Neoplasia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"927079","DOI":"10.3389\/fgene.2022.927079","article-title":"The diagnostic and prognostic value of the miR-17-92 cluster in hepatocellular carcinoma: A meta-analysis","volume":"13","author":"Lu","year":"2022","journal-title":"Front. Genet."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tcb.2014.11.004","article-title":"The biological functions of miRNAs: Lessons from in vivo studies","volume":"25","author":"Vidigal","year":"2015","journal-title":"Trends Cell Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1158\/0008-5472.CAN-06-4218","article-title":"Genetic unmasking of an epigenetically silenced microRNA in human cancer cells","volume":"67","author":"Lujambio","year":"2007","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/npp.2012.87","article-title":"General principals of miRNA biogenesis and regulation in the brain","volume":"38","author":"Schaefer","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1101\/gr.2722704","article-title":"Identification of mammalian microRNA host genes and transcription units","volume":"14","author":"Rodriguez","year":"2004","journal-title":"Genome Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: Target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.molcel.2010.05.015","article-title":"Hsc70\/Hsp90 chaperone machinery mediates ATP-dependent RISC loading of small RNA duplexes","volume":"39","author":"Iwasaki","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_110","first-page":"83","article-title":"MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions","volume":"3","author":"Shukla","year":"2011","journal-title":"Mol. Cell Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fgene.2018.00403","article-title":"Intracytoplasmic Re-localization of miRISC Complexes","volume":"9","author":"Akgul","year":"2018","journal-title":"Front. Genet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1038\/s41467-018-05182-9","article-title":"Endogenous transcripts control miRNA levels and activity in mammalian cells by target-directed miRNA degradation","volume":"9","author":"Ghini","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.molcel.2019.06.019","article-title":"Structural Basis for Target-Directed MicroRNA Degradation","volume":"75","author":"Pawlica","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-pharmtox-010510-100517","article-title":"microRNAs: Master regulators as potential therapeutics in cancer","volume":"51","author":"Garofalo","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nature07228","article-title":"Widespread changes in protein synthesis induced by microRNAs","volume":"455","author":"Selbach","year":"2008","journal-title":"Nature"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Uhlmann, S., Mannsperger, H., Zhang, J.D., Horvat, E., Schmidt, C., K\u00fcblbeck, M., Henjes, F., Ward, A., Tschulena, U., and Zweig, K. (2012). Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol. Syst. Biol., 8.","DOI":"10.1038\/msb.2011.100"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molcel.2007.06.017","article-title":"MicroRNA targeting specificity in mammals: Determinants beyond seed pairing","volume":"27","author":"Grimson","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1093\/nar\/gkm133","article-title":"Distance constraints between microRNA target sites dictate efficacy and cooperativity","volume":"35","author":"Saetrom","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41573-019-0042-3","article-title":"Targeting mRNA processing as an anticancer strategy","volume":"19","author":"Desterro","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"736323","DOI":"10.3389\/fphar.2021.736323","article-title":"MicroRNA as an Important Target for Anticancer Drug Development","volume":"12","author":"Fu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s13577-023-00899-2","article-title":"Dysregulated microRNAs participate in the crosstalk between colorectal cancer and atrial fibrillation","volume":"36","author":"Ding","year":"2023","journal-title":"Hum. Cell"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13148-018-0492-1","article-title":"Circulating microRNAs as potential cancer biomarkers: The advantage and disadvantage","volume":"10","author":"Wang","year":"2018","journal-title":"Clin. Epigenet."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/13543776.2018.1503650","article-title":"Circulating miRNAs as biomarkers for early diagnosis of coronary artery disease","volume":"28","author":"Zhang","year":"2018","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.cell.2007.04.040","article-title":"A mammalian microRNA expression atlas based on small RNA library sequencing","volume":"129","author":"Landgraf","year":"2007","journal-title":"Cell"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1093\/nar\/gkw116","article-title":"Distribution of miRNA expression across human tissues","volume":"44","author":"Ludwig","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Reda El Sayed, S., Cristante, J., Guyon, L., Denis, J., Chabre, O., and Cherradi, N. (2021). MicroRNA Therapeutics in Cancer: Current Advances and Challenges. Cancers, 13.","DOI":"10.3390\/cancers13112680"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2147\/DDDT.S288859","article-title":"The Risks of miRNA Therapeutics: In a Drug Target Perspective","volume":"15","author":"Zhang","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/d41573-019-00014-x","article-title":"2018 FDA drug approvals","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/d41573-020-00001-7","article-title":"2019 FDA drug approvals","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A Review of Patisiran (ONPATTRO\u00ae) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Obici","year":"2016","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev-med-042617-101816","article-title":"Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines","volume":"70","author":"Vormehr","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00251-004-0647-4","article-title":"Definition of supertypes for HLA molecules using clustering of specificity matrices","volume":"55","author":"Lund","year":"2004","journal-title":"Immunogenetics"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid Nanoparticle Systems for Enabling Gene Therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jare.2020.08.012","article-title":"Therapeutic advances of miRNAs: A preclinical and clinical update","volume":"28","author":"Chakraborty","year":"2021","journal-title":"J. Adv. Res."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., and Bahal, R. (2020). Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. J. Clin. Med., 9.","DOI":"10.3390\/jcm9062004"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Jiao, L.R., Frampton, A.E., Jacob, J., Pellegrino, L., Krell, J., Giamas, G., Tsim, N., Vlavianos, P., Cohen, P., and Ahmad, R. (2012). MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032068"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Iacomino, G. (2023). miRNAs: The Road from Bench to Bedside. Genes, 14.","DOI":"10.3390\/genes14020314"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.omtm.2019.09.010","article-title":"AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes","volume":"15","author":"Keskin","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1038\/mtna.2016.7","article-title":"Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington\u2019s Disease","volume":"5","author":"Miniarikova","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/gt.2017.14","article-title":"MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain","volume":"24","author":"Samaranch","year":"2017","journal-title":"Gene Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI75852","article-title":"Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways","volume":"125","author":"Gomez","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1021\/ac403044t","article-title":"Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates","volume":"86","author":"Kelnar","year":"2014","journal-title":"Anal. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","article-title":"Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020","volume":"36","author":"Kashtan","year":"2021","journal-title":"Pediatr. Nephrol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/13543784.2020.1839888","article-title":"The nonalcoholic steatohepatitis (NASH) drug development graveyard: Established hurdles and planning for future success","volume":"29","author":"Drenth","year":"2020","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics","volume":"6","author":"Huang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/wrr.12660","article-title":"A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds","volume":"26","author":"Piper","year":"2018","journal-title":"Wound Repair. Regen."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/nat.2020.0871","article-title":"Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study","volume":"30","author":"Abplanalp","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2217\/epi-2016-0035","article-title":"Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer","volume":"8","author":"Reid","year":"2016","journal-title":"Epigenomics"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"Pavlakis","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: Results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study","volume":"42","author":"Hauke","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehaa791","article-title":"CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure","volume":"42","author":"Batkai","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jid.2018.11.007","article-title":"A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin","volume":"139","author":"Piper","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jcp.21993","article-title":"Genomic organization of microRNAs","volume":"222","author":"Olena","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/AAC.04220-14","article-title":"In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122","volume":"59","author":"Ottosen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/nar\/gkt852","article-title":"Miravirsen (SPC3649) can inhibit the biogenesis of miR-122","volume":"42","author":"Gebert","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nature06783","article-title":"LNA-mediated microRNA silencing in non-human primates","volume":"452","author":"Lindow","year":"2008","journal-title":"Nature"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1178178","article-title":"Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection","volume":"327","author":"Lanford","year":"2010","journal-title":"Science"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(16)31715-9","article-title":"Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: A phase 1B, double-blind, randomised controlled trial","volume":"389","author":"Stelma","year":"2017","journal-title":"Lancet"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/hep.29148","article-title":"Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101","volume":"66","author":"Stelma","year":"2017","journal-title":"Hepatology"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/hon.10_2632","article-title":"SOLAR: A Phase 2, Global, Randomized, Active Comparator Study To Investigate the Efficacy and Safety of Cobomarsen in Subjects with Mycosis Fungoides (MF)","volume":"37","author":"James","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood.V128.22.1829.1829","article-title":"Preliminary Results of a Phase 1 Trial Evaluating MRG-106, a Synthetic microRNA Antagonist (LNA antimiR) of microRNA-155, in Patients with CTCL","volume":"128","author":"Querfeld","year":"2016","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Adams, D., Suhr, O.B., Dyck, P.J., Litchy, W.J., Leahy, R.G., Chen, J., Gollob, J., and Coelho, T. (2017). Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol., 17.","DOI":"10.1186\/s12883-017-0948-5"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Raue, R., Frank, A.C., Syed, S.N., and Brune, B. (2021). Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042210"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41419-018-1176-7","article-title":"Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a\/Bad\/Bax axis","volume":"9","author":"Ge","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1089\/ars.2013.5639","article-title":"HypoxamiRs and cancer: From biology to targeted therapy","volume":"21","author":"Gee","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.yexcr.2018.05.013","article-title":"miR-301a plays a pivotal role in hypoxia-induced gemcitabine resistance in pancreatic cancer","volume":"369","author":"Luo","year":"2018","journal-title":"Exp. Cell Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1038\/oncsis.2014.11","article-title":"MiRNA-99a directly regulates AGO2 through translational repression in hepatocellular carcinoma","volume":"3","author":"Zhang","year":"2014","journal-title":"Oncogenesis"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"eabd6764","DOI":"10.1126\/sciadv.abd6764","article-title":"Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy","volume":"6","author":"Xin","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3389\/fgene.2019.00478","article-title":"The Potential for microRNA Therapeutics and Clinical Research","volume":"10","author":"Hanna","year":"2019","journal-title":"Front. Genet."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1083\/jcb.201208082","article-title":"Discovering the first microRNA-targeted drug","volume":"199","author":"Lindow","year":"2012","journal-title":"J. Cell Biol."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Huang, P.S., Liao, C.J., Huang, Y.H., Yeh, C.T., Chen, C.Y., Tang, H.C., Chang, C.C., and Lin, K.H. (2021). Functional and Clinical Significance of Dysregulated microRNAs in Liver Cancer. Cancers, 13.","DOI":"10.3390\/cancers13215361"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cmdc.201000156","article-title":"Off-target effects related to the phosphorothioate modification of nucleic acids","volume":"5","author":"Winkler","year":"2010","journal-title":"ChemMedChem"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12263-017-0577-z","article-title":"Role of microRNAs in obesity and obesity-related diseases","volume":"12","author":"Iacomino","year":"2017","journal-title":"Genes Nutr."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-20-3139","article-title":"Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo","volume":"27","author":"Anastasiadou","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1152\/physiolgenomics.00173.2011","article-title":"MiR-382 targeting of kallikrein 5 contributes to renal inner medullary interstitial fibrosis","volume":"44","author":"Kriegel","year":"2012","journal-title":"Physiol. Genom."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s40265-022-01745-9","article-title":"Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease","volume":"82","author":"Bais","year":"2022","journal-title":"Drugs"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"10164","DOI":"10.18632\/oncotarget.24309","article-title":"The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer","volume":"9","author":"Chakraborty","year":"2018","journal-title":"Oncotarget"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1517\/14712598.2015.1030390","article-title":"The emerging role of miRNAs in combined cancer therapy","volume":"15","author":"Yu","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1535-7163.MCT-19-0510","article-title":"Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids","volume":"19","author":"Vernon","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.7150\/ijbs.47203","article-title":"miRNA-based biomarkers, therapies, and resistance in Cancer","volume":"16","author":"He","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41570-020-0201-4","article-title":"Inhibition of RNA-binding proteins with small molecules","volume":"4","author":"Wu","year":"2020","journal-title":"Nat. Rev. Chem."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2005.01.006","article-title":"The fundamental role of epigenetics in hematopoietic malignancies","volume":"20","author":"Galm","year":"2006","journal-title":"Blood Rev."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1073\/pnas.1014720108","article-title":"Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing","volume":"108","author":"Melo","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1200\/JCO.2005.05.5194","article-title":"MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior","volume":"24","author":"Roldo","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12022-007-0023-7","article-title":"Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues","volume":"18","author":"Tetzlaff","year":"2007","journal-title":"Endocr. Pathol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1038\/sj.onc.1210856","article-title":"MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer","volume":"27","author":"Asangani","year":"2008","journal-title":"Oncogene"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4161\/cbt.10.12.14252","article-title":"MicroRNA-21: A novel therapeutic target in human cancer","volume":"10","author":"Pan","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"24707","DOI":"10.1074\/jbc.M109.062976","article-title":"Identification of small molecules that suppress microRNA function and reverse tumorigenesis","volume":"285","author":"Watashi","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/anie.201106455","article-title":"The tuberculosis drug streptomycin as a potential cancer therapeutic: Inhibition of miR-21 function by directly targeting its precursor","volume":"51","author":"Bose","year":"2012","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/0008-5472.CAN-13-0280","article-title":"AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression","volume":"73","author":"Shi","year":"2013","journal-title":"Cancer Res."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"7482","DOI":"10.1002\/anie.200801555","article-title":"Small-molecule inhibitors of microrna miR-21 function","volume":"47","author":"Gumireddy","year":"2008","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1093\/nar\/gkp117","article-title":"Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells","volume":"37","author":"Wickramasinghe","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1016\/j.bmcl.2015.07.016","article-title":"Aryl amide small-molecule inhibitors of microRNA miR-21 function","volume":"25","author":"Naro","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1016\/j.bmc.2015.08.007","article-title":"Discovery of 4-benzoylamino-N-(prop-2-yn-1-yl)benzamides as novel microRNA-21 inhibitors","volume":"23","author":"Jiang","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1002\/anie.200601332","article-title":"A homogenous assay for micro RNA maturation","volume":"45","author":"Davies","year":"2006","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.1021\/ja910275u","article-title":"Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma","volume":"132","author":"Young","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jhep.2008.01.019","article-title":"miR-122, a paradigm for the role of microRNAs in the liver","volume":"48","author":"Girard","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2006.01.005","article-title":"miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting","volume":"3","author":"Esau","year":"2006","journal-title":"Cell Metab."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nchembio.1452","article-title":"Sequence-based design of bioactive small molecules that target precursor microRNAs","volume":"10","author":"Velagapudi","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cvr\/cvn137","article-title":"MicroRNAs: Novel regulators in cardiac development and disease","volume":"79","author":"Thum","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Wystub, K., Besser, J., Bachmann, A., Boettger, T., and Braun, T. (2013). miR-1\/133a clusters cooperatively specify the cardiomyogenic lineage by adjustment of myocardin levels during embryonic heart development. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003793"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1016\/j.bmc.2013.04.058","article-title":"Small molecular inhibitors of miR-1 identified from photocycloadducts of acetylenes with 2-methoxy-1,4-naphthalenequinone","volume":"21","author":"Tan","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbrc.2015.11.071","article-title":"Arsenic trioxide suppresses cell growth and migration via inhibition of miR-27a in breast cancer cells","volume":"469","author":"Zhang","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1021\/cb300650y","article-title":"A molecular-beacon-based screen for small molecule inhibitors of miRNA maturation","volume":"8","author":"Bose","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1021\/acschembio.5b00615","article-title":"Small Molecule Targeting of a MicroRNA Associated with Hepatocellular Carcinoma","volume":"11","author":"Disney","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1261\/rna.042911.113","article-title":"Association of a peptoid ligand with the apical loop of pri-miR-21 inhibits cleavage by Drosha","volume":"20","author":"Diaz","year":"2014","journal-title":"RNA"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.addr.2014.05.009","article-title":"In vivo delivery of miRNAs for cancer therapy: Challenges and strategies","volume":"81","author":"Chen","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41544-019-0024-y","article-title":"Recent progress in microRNA-based delivery systems for the treatment of human disease","volume":"1","author":"Fu","year":"2019","journal-title":"ExRNA"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1021\/acsmaterialsau.2c00042","article-title":"Gold Nanoconjugates for miRNA Modulation in Cancer Therapy: From miRNA Silencing to miRNA Mimics","volume":"2","author":"Sousa","year":"2022","journal-title":"ACS Mater. Au"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.nano.2016.06.004","article-title":"Ligand-targeted bacterial minicells: Futuristic nano-sized drug delivery system for the efficient and cost effective delivery of shRNA to cancer cells","volume":"12","author":"Jivrajani","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Dasgupta, I., and Chatterjee, A. (2021). Recent Advances in miRNA Delivery Systems. Methods Protoc., 4.","DOI":"10.3390\/mps4010010"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41565-023-01447-7","article-title":"Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles","volume":"18","author":"Dosta","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/mt.2008.103","article-title":"Recombinant adeno-associated virus transduction and integration","volume":"16","author":"Schultz","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/hgtb.2017.036","article-title":"Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors","volume":"28","author":"Liu","year":"2017","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.2147\/IDR.S315727","article-title":"Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety","volume":"14","author":"Mascellino","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Monahan, P.E., N\u00e9grier, C., Tarantino, M., Valentino, L.A., and Mingozzi, F. (2021). Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112471"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","article-title":"Extracellular vesicles as drug delivery systems: Why and how?","volume":"159","author":"Elsharkasy","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Baldari, S., Di Rocco, G., Magenta, A., Picozza, M., and Toietta, G. (2019). Extracellular Vesicles-Encapsulated MicroRNA-125b Produced in Genetically Modified Mesenchymal Stromal Cells Inhibits Hepatocellular Carcinoma Cell Proliferation. Cells, 8.","DOI":"10.3390\/cells8121560"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: Current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.omtn.2018.09.016","article-title":"Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells","volume":"13","author":"Russo","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejmech.2016.01.047","article-title":"Chemical modifications in the seed region of miRNAs 221\/222 increase the silencing performances in gastrointestinal stromal tumor cells","volume":"111","author":"Durso","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1042\/bj3400783","article-title":"Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo","volume":"340 Pt. 3","author":"Biessen","year":"1999","journal-title":"Biochem. J."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Yamamoto, T., Mukai, Y., Wada, F., Terada, C., Kayaba, Y., Oh, K., Yamayoshi, A., Obika, S., and Harada-Shiba, M. (2021). Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13060817"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1002\/jcp.29584","article-title":"Inhibition of miR-155 in MCF-7 breast cancer cell line by gold nanoparticles functionalized with antagomir and AS1411 aptamer","volume":"235","author":"Kardani","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_244","first-page":"271","article-title":"Recent advances in biomaterials for 3D scaffolds: A review","volume":"4","author":"Nikolova","year":"2019","journal-title":"Bioact. Mater."},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Aguilar-de-Leyva, \u00c1., Linares, V., Casas, M., and Caraballo, I. (2020). 3D Printed Drug Delivery Systems Based on Natural Products. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12070620"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s12015-021-10120-2","article-title":"3D Printed Bioconstructs: Regenerative Modulation for Genetic Expression","volume":"17","author":"Shende","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/gt.2011.100","article-title":"Chemical modification and design of anti-miRNA oligonucleotides","volume":"18","author":"Lennox","year":"2011","journal-title":"Gene Ther."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00063030-200721040-00004","article-title":"Locked nucleic acid oligonucleotides: The next generation of antisense agents?","volume":"21","author":"Hartmann","year":"2007","journal-title":"BioDrugs"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1016\/S0040-4020(98)00094-5","article-title":"LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition","volume":"54","author":"Koshkin","year":"1998","journal-title":"Tetrahedron"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1093\/nar\/gkaa576","article-title":"A critical analysis of methods used to investigate the cellular uptake and subcellular localization of RNA therapeutics","volume":"48","author":"Deprey","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drudis.2017.09.018","article-title":"Locked nucleic acid: Modality, diversity, and drug discovery","volume":"23","author":"Hagedorn","year":"2018","journal-title":"Drug Discovery Today"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/nat.2017.0709","article-title":"Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver","volume":"28","author":"Miller","year":"2018","journal-title":"Nucleic Acid. Ther."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/ki.1995.205","article-title":"Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy","volume":"47","author":"Rappaport","year":"1995","journal-title":"Kidney Int."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature13905","article-title":"MicroRNA silencing for cancer therapy targeted to the tumour microenvironment","volume":"518","author":"Cheng","year":"2015","journal-title":"Nature"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1073\/pnas.0601463103","article-title":"Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix","volume":"103","author":"Reshetnyak","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s40265-021-01582-2","article-title":"Comment on: \u201cMicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19\u201d","volume":"81","author":"Zhang","year":"2021","journal-title":"Drugs"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/wrna.1134","article-title":"Computational analysis of noncoding RNAs","volume":"3","author":"Washietl","year":"2012","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/bib\/bbz111","article-title":"What\u2019s the target: Understanding two decades of in silico microRNA-target prediction","volume":"21","author":"Kern","year":"2020","journal-title":"Brief. Bioinform."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1126\/science.aav1741","article-title":"The biochemical basis of microRNA targeting efficacy","volume":"366","author":"McGeary","year":"2019","journal-title":"Science"},{"key":"ref_260","doi-asserted-by":"crossref","unstructured":"John, B., Enright, A.J., Aravin, A., Tuschl, T., Sander, C., and Marks, D.S. (2004). Human MicroRNA targets. PLoS Biol., 2.","DOI":"10.1371\/journal.pbio.0020363"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"71514","DOI":"10.18632\/oncotarget.11723","article-title":"Paired proteomics, transcriptomics and miRNomics in non-small cell lung cancers: Known and novel signaling cascades","volume":"7","author":"Backes","year":"2016","journal-title":"Oncotarget"},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Jung, D., Kim, B., Freishtat, R.J., Giri, M., Hoffman, E., and Seo, J. (2015). miRTarVis: An interactive visual analysis tool for microRNA-mRNA expression profile data. BMC Proc., 9.","DOI":"10.1186\/1753-6561-9-S6-S2"},{"key":"ref_263","doi-asserted-by":"crossref","unstructured":"Licursi, V., Conte, F., Fiscon, G., and Paci, P. (2019). MIENTURNET: An interactive web tool for microRNA-target enrichment and network-based analysis. BMC Bioinform., 20.","DOI":"10.1186\/s12859-019-3105-x"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"W252","DOI":"10.1093\/nar\/gkaa259","article-title":"miRViz: A novel webserver application to visualize and interpret microRNA datasets","volume":"48","author":"Giroux","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"W244","DOI":"10.1093\/nar\/gkaa467","article-title":"miRNet 2.0: Network-based visual analytics for miRNA functional analysis and systems biology","volume":"48","author":"Chang","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_266","doi-asserted-by":"crossref","unstructured":"Preusse, M., Theis, F.J., and Mueller, N.S. (2016). miTALOS v2: Analyzing Tissue Specific microRNA Function. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151771"},{"key":"ref_267","doi-asserted-by":"crossref","unstructured":"Laczny, C., Leidinger, P., Haas, J., Ludwig, N., Backes, C., Gerasch, A., Kaufmann, M., Vogel, B., Katus, H.A., and Meder, B. (2012). miRTrail\u2014A comprehensive webserver for analyzing gene and miRNA patterns to enhance the understanding of regulatory mechanisms in diseases. BMC Bioinform., 13.","DOI":"10.1186\/1471-2105-13-36"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/nar\/gkaa1161","article-title":"Validation of human microRNA target pathways enables evaluation of target prediction tools","volume":"49","author":"Kern","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"W409","DOI":"10.1093\/nar\/gkab297","article-title":"miRTargetLink 2.0-interactive miRNA target gene and target pathway networks","volume":"49","author":"Kern","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"D142","DOI":"10.1093\/nar\/gkz1022","article-title":"miRPathDB 2.0: A novel release of the miRNA Pathway Dictionary Database","volume":"48","author":"Kehl","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"D360","DOI":"10.1093\/nar\/gkx1144","article-title":"mirDIP 4.1-integrative database of human microRNA target predictions","volume":"46","author":"Tokar","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"W515","DOI":"10.1093\/nar\/gkaa306","article-title":"GeneTrail 3: Advanced high-throughput enrichment analysis","volume":"48","author":"Gerstner","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1093\/nar\/gkw550","article-title":"Understanding microRNA-mediated gene regulatory networks through mathematical modelling","volume":"44","author":"Lai","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_274","doi-asserted-by":"crossref","unstructured":"Zhao, C., Zhang, Y., and Popel, A.S. (2019). Mechanistic Computational Models of MicroRNA-Mediated Signaling Networks in Human Diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020421"},{"key":"ref_275","doi-asserted-by":"crossref","unstructured":"Lekprasert, P., Mayhew, M., and Ohler, U. (2011). Assessing the utility of thermodynamic features for microRNA target prediction under relaxed seed and no conservation requirements. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020622"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1152\/physrev.00039.2017","article-title":"Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development","volume":"99","author":"Karagiannis","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/stem.2926","article-title":"Concise Review: Laying the Groundwork for a First-In-Human Study of an Induced Pluripotent Stem Cell-Based Intervention for Spinal Cord Injury","volume":"37","author":"Tsuji","year":"2019","journal-title":"Stem Cells"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41580-018-0045-7","article-title":"Regulation of microRNA function in animals","volume":"20","author":"Gebert","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.molcel.2010.11.038","article-title":"The miR-17-92 microRNA cluster regulates multiple components of the TGF-\u03b2 pathway in neuroblastoma","volume":"40","author":"Mestdagh","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_280","first-page":"4607","article-title":"Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis","volume":"11","author":"Borsuk","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1158\/1535-7163.MCT-14-0209","article-title":"Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer","volume":"13","author":"Daige","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-4939-2727-2_8","article-title":"A qRT-PCR Method for Determining the Biodistribution Profile of a miR-34a Mimic","volume":"1317","author":"Kelnar","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41419-018-1050-7","article-title":"Modulation of intracellular calcium signaling by microRNA-34a-5p","volume":"9","author":"Diener","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"e001617","DOI":"10.1136\/jitc-2020-001617","article-title":"Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10\/CXCL11\/CXCR3-axis in CD4(+), CD8(+) T cells, and M1 macrophages","volume":"8","author":"Hart","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.cell.2023.02.031","article-title":"Delivering the next generation of cancer immunotherapies with RNA","volume":"186","author":"Raimondo","year":"2023","journal-title":"Cell"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"e1640","DOI":"10.1002\/wrna.1640","article-title":"Artificial miRNAs as therapeutic tools: Challenges and opportunities","volume":"12","author":"Pewinska","year":"2021","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.3324\/haematol.2018.209437","article-title":"miR-101 suppresses the development of MLL-rearranged acute myeloid leukemia","volume":"104","author":"Connerty","year":"2019","journal-title":"Haematologica"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-017-0751-3","article-title":"The Jun\/miR-22\/HuR regulatory axis contributes to tumourigenesis in colorectal cancer","volume":"17","author":"Liu","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1038\/s41375-020-0768-2","article-title":"Restoration of microRNA function impairs MYC-dependent maintenance of MLL leukemia","volume":"34","author":"Zhu","year":"2020","journal-title":"Leukemia"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1469\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:49:03Z","timestamp":1760104143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":291,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ijms25031469"],"URL":"https:\/\/doi.org\/10.3390\/ijms25031469","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]}}}